DA Davidson & Co Reiterates Buy Rating for USANA Health Sciences

DA Davidson & Co reiterates its Buy rating for USANA Health Sciences

following the company's Q4 2011 earnings results. Its price target on the company remains $46. In the report, DA Davidson & Co writes, "USANA Health Sciences reported Q4 operating EPS of $0.87, up 15.3% from $0.75 last year. Net sales of $146 million increased 6.1% year-over-year, in line with our expectation. USANA's shares remain very attractive and our price target remains $46." USANA Health Sciences are currently trading at $36.57, up 2.09% from yesterday's close.